Skip to main content
Premium Trial:

Request an Annual Quote

OraSure to Buy DNA Genotek for $53M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OraSure Technologies announced after the close of the market on Monday that it is acquiring DNA Genotek for $53 million in cash.

The deal, which is expected to be completed in the third quarter, will provide OraSure, based in Bethlehem, Pa., with a complementary portfolio of products for the collection, stabilization, transportation, and storage of high quality nucleic acid samples, the company said.

It also provides OraSure, whose products include antibody-based assays for infectious diseases, with a presence in the molecular diagnostics space. In a statement, Douglas Michels, president and CEO of OraSure, said that his firm has "targeted entry into the US $4 billion molecular diagnostics market given the magnitude and rapid growth profile of the segment."

Headquartered in Ottawa, DNA Genotek develops products to collect, stabilize, and prepare oral fluid samples for molecular diagnostic applications. Its lead product is the Oragene DNA sample collection kit. The company is currently seeking clearance from the US Food and Drug Administration for Oragene products.

In 2010, DNA Genotek generated approximately $14 million in revenues, OraSure said.

It added that the acquisition is expected to be neutral to non-GAAP earnings, excluding transaction costs and required acquisition accounting adjustments, and to be accretive to revenue growth in 2012 and beyond. Following completion of the deal, DNA Genotek will operate as a wholly-owned subsidiary of OraSure.

Deutsche Bank Securities was the advisor to OraSure on the deal. Moelis & Co. advised DNA Genotek.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.